Company · founded 2005

Integrated BioTherapeutics (United States)

Gaithersburg, United States · integratedbiotherapeutics.com

Manage this page

Citations, last 5 years: 177
Works, last 5 years: 31
h-index: 76
Scientists listed: 2
Grants since 2016: 78

Grants received

2019–2021 · research · R43

Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma

Dianna Ammons Johnson · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$225kGlaucoma and retinal disorders

2019–2020 · research · R43

Development of a chemically regulated immunotherapy for B-cell malignancies

Erin Forbes Simonds · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$299.6kCAR-T cell therapy research

2019–2023 · research · R44

Development of a Universal Immunotherapeutic for Influenza Viruses

Frederick Wayne Holtsberg · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$804.2kInfluenza Virus Research Studies

2019–2022 · research · R41

Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$300kViral Infections and Outbreaks Research

2019–2020 · research · R44

Effects of Abscisic Acid on Insulin Sensitivity

Raquel Hontecillas · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$281.6kCalcium signaling and nucleotide metabolism

2019 · research · R43

Immunometabolic NLRX1 Therapeutics for IBD

Andrew Leber · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$233.2k

2019–2022 · research · R43

Mining natively paired macque antibodies for Marburg virus protective antibodies

Shweta Kailasan · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$300kViral Infections and Outbreaks Research

2018–2020 · research · R43

Remodeled glycoprotein for broad protection against ebolaviruses

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$299.2kViral Infections and Outbreaks Research

2018–2019 · research · R43

Remodeled glycoprotein for broad protection against ebolaviruses

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$302.5kViral Infections and Outbreaks Research

2018–2019 · research · R44

BT-11: A First-in-class Oral Therapeutic for Inflammatory Bowel Disease

Josep Bassaganya-Riera · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$299.6k

2017–2018 · research · R43

Serotype independent therapeutic vaccine for Streptococcus pneumoniae

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$247.5kPneumonia and Respiratory Infections

2017–2019 · research · R41

Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

Rajan P Adhikari · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$300kBacillus and Francisella bacterial research

2017–2022 · research · R01

Rationally Designed Pan-Ebolavirus Vaccine

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$1.2MViral Infections and Outbreaks Research

2017–2022 · research · R01

Rationally Designed Pan-Ebolavirus Vaccine

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$1.7MViral Infections and Outbreaks Research

2017–2022 · research · R01

Rationally Designed Pan-Ebolavirus Vaccine

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$1.4MViral Infections and Outbreaks Research

2017–2022 · research · R42

Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

Rajan P Adhikari · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$1,000kBacillus and Francisella bacterial research

2017–2022 · research · R01

Rationally Designed Pan-Ebolavirus Vaccine

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$1.2MViral Infections and Outbreaks Research

2017–2022 · research · R01

Evolution of anti-filovirus B cell responses and mechanisms of protection

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$742.5kViral Infections and Outbreaks Research

2017–2022 · research · R01

Evolution of anti-filovirus B cell responses and mechanisms of protection

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$738.6kViral Infections and Outbreaks Research

2017–2019 · research · R41

Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

Rajan P Adhikari · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$294.9kBacillus and Francisella bacterial research

2017–2023 · research · R01

Rationally Designed Pan-Ebolavirus Vaccine

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$886.7kViral Infections and Outbreaks Research

2017–2022 · research · R01

Evolution of anti-filovirus B cell responses and mechanisms of protection

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$754.2kViral Infections and Outbreaks Research

2017–2022 · research · R42

Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

Rajan P Adhikari · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$985.3kBacillus and Francisella bacterial research

2017–2022 · research · R01

Evolution of anti-filovirus B cell responses and mechanisms of protection

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$750.1kViral Infections and Outbreaks Research

2017–2023 · research · R42

Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

Rajan P Adhikari · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$663.3kBacillus and Francisella bacterial research

2017–2023 · research · R01

Evolution of anti-filovirus B cell responses and mechanisms of protection

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$733.2kViral Infections and Outbreaks Research

2017–2019 · research · R43

Serotype independent therapeutic vaccine for Streptococcus pneumoniae

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$191.3kPneumonia and Respiratory Infections

2016–2022 · research · R44

Assessment of Multiple Dose Administration ofGlucagon Receptor Blocker REMD477 in Type 1 Diabetes

Samuel Klein · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$993.8kDiabetes Management and Research

2016–2018 · research · R43

Structure-guided redesign of monoclonal antibodies targeting conserved filovirus epitopes

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$284.4kViral Infections and Outbreaks Research

2016–2021 · research · R42

Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$1MViral Infections and Outbreaks Research

2016–2019 · research · R42

Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

Samuel Klein · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$748.1kDiabetes Management and Research

2016–2017 · research · R41

Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$230kViral Infections and Outbreaks Research

2016–2019 · research · R42

Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

Samuel Klein · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$680.9kDiabetes Management and Research

2016–2019 · research · R42

Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$861.3kViral Infections and Outbreaks Research

2016–2022 · research · R44

Assessment of Multiple Dose Administration ofGlucagon Receptor Blocker REMD477 in Type 1 Diabetes

Samuel Klein · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$993.8kDiabetes Management and Research

2016–2022 · research · R44

Assessment of Multiple Dose Administration of Glucagon Receptor Blocker REMD477 in Type 1 Diabetes

Samuel Klein · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$993.3kDiabetes Management and Research

2015–2020 · research · R01

Multivalent Toxoid Vaccine for Prevention of S. aureus Invasive Diseases

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$761.8kAntimicrobial Resistance in Staphylococcus

2014–2023 · research · R01

Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease

M Javad Aman · Integrated BioTherapeutics (United States) · funded by National Institutes of Health

$702.9kAntimicrobial Resistance in Staphylococcus